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Type 1 DiabetesPrevious studies have suggested that the ancestral haplotype 18.2 (AH18.2) carries additional susceptibility
gene to Type 1 Diabetes (T1D) on the Major Histocompatibility Complex (MHC). We analyzed 10 DR3/
TNFa1b5 homozygous subjects in order to establish the conservation of the AH18.2 and then compared this
conserved region with other DR3 haplotype, the AH8.1. The Illumina's HumanHap550 Bead chip was used to
perform an extensive genotyping of the MHC region.
The AH18.2 was highly conserved between DDR1 and HLA-DQA1 genes; therefore most probably the
second susceptibility gene is located within this region. We can exclude the region centromeric to HLA-DRA
gene and telomeric to DDR1 gene. A comparison between the AH18.2 and AH8.1 haplotypes showed that 233
SNPs were different in the aforementioned conserved region.
These data suggest that the 1.65 Mb MHC region between DDR1 and HLA-DRA genes is likely to carry
additional susceptibility alleles for T1D on the AH18.2 haplotype.
© 2009 Elsevier Inc. All rights reserved.Introduction
Type 1 Diabetes (T1D) is a genetically complex autoimmune
disease in which the interaction of genetic and environmental factors
causes the selective destruction of pancreatic beta cells. The genetic
predisposition to T1D is strongly associated with the MHC chromo-
somal region, although some genes outside of the MHC class II also
contribute to disease risk [1–3]. In the last few years accumulated
evidence suggests that the class II loci cannot explain the entire
genetic susceptibility conferred by the MHC for a number of different
autoimmune diseases, including Rheumatoid Arthritis (RA) [1] and
Multiple Sclerosis (MS) [4], as well as T1D [1,3].
It is generally accepted that the MHC class II loci are likely to be
directly involved in diabetes risk, with the highest risk conferred by
the haplotypes DR3–DQ2 and DR4–DQ8 [5–7]. However, several
studies have shown that the various DR3–DQ2 haplotypes do not
predispose equally to the disease [8–12]. Two conserved ancestral or
extended DR3–DQ2 haplotypes have been associated with diabetes
susceptibility [13]: AH8.1 (also known as COX) and AH18.2 (also
known as QBL). Both haplotypes carry the same HLA-DR and HLA-DQ
alleles but the AH18.2 haplotype confers signiﬁcantly increased risk
compared with other DR3–DQ2 bearing haplotypes, and thereforeartín Lagos s/n, 28040Madrid,
ll rights reserved.may carry additional susceptibility genes for T1D [9,10,12]. Moreover,
no differences exist in diabetes risk between AH8.1 and other DR3–
DQ2 haplotypes different from AH18.2 [14].
Further delineation of the extent of conservation of the AH18.2
haplotype would be useful for narrowing down the possible regions
involved in T1D susceptibility. Our ﬁrst results are presented in this
report, using a panel of over 2000 SNPs across the MHC. We aimed at
excluding non-conserved regions within this haplotype as carriers of
the risk determinant. Obviously, the genetic determinant present in
AH18.2 will be shared by the conserved portion of the haplotype. For
doing so, 10 homozygous subjects for AH18.2 were compared. For
comparison purposes AH18.2 bearers are all useful, regardless their
patient/control status.
It is well known that polygenic diseases result from the
concurrence of genetic risk factors each rendering a modest increase
in susceptibility. Separately, none of them is sufﬁcient/necessary to
develop the disease, but a combination is needed to trigger the
pathogenic condition. Consequently, healthy subjects may carry a
speciﬁc susceptibility factor; i.e. around 90% of celiac disease patients
carry DQ2 alleles, present as well in healthy controls (up to 20%) [15].
Results
In DR3 subjects, the TNF microsatellite alleles TNFa1b5 and
TNFa2b3 are haplo-speciﬁc for AH18.2 and AH8.1 haplotypes
respectively, in both Caucasian Spanish and Caucasian American
populations [11,16]. We used these polymorphisms to identify the
Fig. 1. Haplotypes from 10 homozygous AH18.2 individuals constructed by fastPHASE and the position of HLA-A, HLA-B, and DRB1 genes. Blue means match with inferred allele of
AH18.2 and yellow no match. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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subjects for AH18.2 haplotype from a Spanish population (DR3/DR3–
TNFa1b5/a1b5). Eight of themwere T1D patients (samples S1 to S8 in
Supplementary Table 1) and twowere controls (samples S9 and S10 in
Supplementary Table 1). We used Spanish samples because the
prevalence of AH18.2 haplotypes is high in southern European
population. SNPs present on the Illumina HumanHap550 Bead chip
were genotyped and after 95% call rate clean up performed with the
HelixTree program, we analyzed 2022 SNPs in theMHC region (26.03–
33.60 Mb interval) (see Supplementary Table 1). Haplotypes were
reconstructed using fastPHASE and then the 20 haplotypes were
compared with the inferred AH18.2 (Fig. 1). The match (blue in Fig. 1)Fig. 2. Frequency of AH18.2 consensus allele in the ten Spanish homozygous samples. The n
each gene.is high between the region centromeric to HLA-A gene and telomeric
to HLA-DRB1 gene. The frequency of homozygosity for the consensus
AH18.2 allele was near to 1 for SNPs between DDR1 and the HLA-DQA1
genes (HLA-DQA1 is located between HLA-DRB1 and HLA-DQA2, see
Fig. 2). One of the controls (sample S9, second from the bottom in
Fig. 1) showed a shorter region of homozygosity likely reﬂecting a
recombination event for this individual.
We also performed the analysis of 20 individuals homozygous
for the AH8.1 from the Caucasian U.S. population. As expected, and
similarly to the pattern seen for AH18.2, a large fraction of the
subjects displayed homozygosity across the entire MHC region (data
not shown), emphasizing the extreme haplotypic conservation of theumbers in brackets below genes mean the SNP position for ﬁrst to last SNP included in
Table 1
Percentage of different SNPs between AH18.2 and AH8.1 in the 68 genes that map in the
MHC region between DDR1 and HLA-DRA genes.
Gene % of different SNPs
DDR1 28.00
VARSL 71.43
SFTPG 40.00
DPCR1 50.00
MUC21 28.57
C6orf15 26.92
CDSN 28.57
PSORS1C1 61.54
PSORS1C2 33.33
CCHCR1 56.25
TCF19 75.00
POU5F1 40.00
HCG27 36.84
HLA-C 42.86
HLA-B 34.38
MICA 40.00
HCP5 22.86
MICB 41.18
MCCD1 42.86
BAT1 66.67
ATP6V1G2 0.00
NFKBIL1 28.57
LTA 33.33
TNF 100.00
LST1 0.00
NCR3 20.00
AIF1 0.00
BAT2 0.00
BAT3 12.50
C6orf47 50.00
BAT4 0.00
LY6G5B 33.33
LY6G5C 0.00
BAT5 50.00
LY6G6F 50.00
LY6G6E 100.00
LY6G6D 0.00
LY6G6C 50.00
MSH5 25.00
C6orf27 0.00
LSM2 100.00
HSPA1L 0.00
HSPA1B 0.00
C6orf48 33.33
NEU1 0.00
SLC44A4 0.00
EHMT2 33.33
ZBTB12 100.00
C2 0.00
CFB 33.33
RDBP 100.00
SKIV2L 42.86
STK19 33.33
TNXB 7.69
ATF6B 0.00
PRRT1 0.00
PPT2 0.00
EGFL8 100.00
AGPAT1 50.00
RNF5 50.00
AGER 33.33
PBX2 100.00
GPSM3 50.00
NOTCH4 36.36
LOC401252 50.00
C6orf10 34.15
BTNL2 37.04
HLA-DRA 50.00
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published data suggest that the extended AH18.2 haplotype contains
risk alleles for T1D that are not present on the AH8.1, we
characterized the differences and similarities of SNP alleles in thesehaplotypes for all the genes between DDR1 and HLA-DRA (Supple-
mentary Table 2). When we grouped by genes the 646 SNPs studied
in this region of homozygosity between DDR1 and HLA-DRA, we
found 68 genes (Table 1): 18 located in class I, 48 in class III and only
two genes mapped in class II region. Note that 413 SNP alleles within
these genes are identical between the two haplotypes, and all the
alleles in HLA-DRB1 (6 SNPs) and HLA-DQA1 (11 SNPs) were identical
in AH18.2 and AH8.1 haplotypes, as expected (see Supplementary
Table 2). In the MHC class III region 16 out of the 48 genes carried the
same allele in both AH18.2 and AH8.1 haplotypes for all the SNPs
studied. These 16 genes are: ATPase, H+ transporting, lysosomal
13 kDa, V1 subunit G2 (ATP6V1G2), leukocyte speciﬁc transcript 1
(LST1), allograft inﬂammatory factor 1 (AIF1), HLA-B associated
transcript 2 and 4 (BAT2 and BAT4), lymphocyte antigen 6 complex,
locus G5C andG6D (LY6G5C and LY6G6D), chromosome6 open reading
frame 27 (C6orf27), heat shock 70 KDa protein 1-like and 1B (HSPA1
and HSPA1B), sialidase 1 (NEU1), solute carrier family 44 member 4
(SLC44A4), complement component 2 (C2), cAMP responsive element
binding protein-like 1 ATF6B proline-rich transmembrane protein 1
(PRRT1) and palmitoil-protein thioesterase 2 (PPT2).
TheMHC class I region under study comprised of 18 genes between
the tyrosine kinase discoidin domain receptor family, member 1
(DDR1) and the highly polymorphic MHC class I chain-related gene B
(MICB). All of them presented differences in markers and some have
an important role in the immune response: HLA-C, HLA-B and the
highly polymorphic MHC class I chain-related gene A and B (MICA and
MICB). As well as MHC class I region, the genes found in class II (BTNL2
and HLA-DRA), showed differences in 37% and 50% of the SNPs under
study, respectively (Table 1).
Discussion
We have previously reported that the AH18.2 haplotype confers a
higher risk than the AH8.1 haplotype to suffer T1D in our Spanish
population [11]. Our criteria in order to select AH18.2 subjects were
the presence of DRB1⁎0301 allele and TNFa1b5 haplotype because
these TNF alleles are haplo-speciﬁc and closer to the HLA-DRB1 gene
than the other speciﬁc alleles (HLA-B⁎18 and HLA-A⁎30). By screening
AH18.2 haplotypes in 10 subjects homozygous for DR3–DQ2 and
TNFa1b5, we observed that substantial conservation extends from the
DDR1 locus, centromeric to HLA-A, all the way to the HLA-DRA gene in
class II region. Thus, it is likely that the speciﬁc T1D risk alleles
conferred by the AH18.2 haplotype reside in this region. We have
further compared the allelic variation between the AH18.2 and AH8.1
haplotypes using our panel of SNPs, and showed that many alleles are
shared between these two extended haplotypes. Therefore, these
particular alleles cannot be responsible for the increased T1D risk
speciﬁcally conferred by the AH18.2 haplotype. Of course, this analysis
leaves us with a large number of genes and polymorphisms to explore.
Some of them are listed in Table 1, but the overall sequence difference
between the AH18.2 and AH8.1 haplotypes is clearly much more
extensive than this and, as reported, involves 15,345 SNPs in the MHC
region, where near 40% of them were different between both
haplotypes [17].
Even though AH18.2 and AH8.1 haplotypes are generally highly
conserved, there is clear evidence of historical meiotic recombination
that breaks these large haplotypes up in the population, and these
recombinants should be useful for estimating the location of risk
genes. By taking a comprehensive approach to the analysis of large
populations of T1D cases and controls in the Spanish population, we
anticipated that the critical risk region on the AH18.2 haplotype can be
further narrowed. The process would be analogous to the analysis
using microsatellite markers that was carried out for the AH8.1
haplotype in the context of systemic lupus [18]. The current analysis
indicates that such an approach can be applied to the study of the
AH18.2 haplotype in populations where this haplotype is common.
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disequilibrium test (TDT), a 2.35 Mb region between microsatellite
D6S2702 (located 970 kb telomeric of HLA-B) and HLA-DOB (centro-
meric to HLA-DQB2) was delineated as the most likely location for the
second risk locus in the AH 18.2 haplotype [8]. The analysis of our data
showed that the conserved AH18.2 haplotype does not extend so far
away. In our homozygous samples, homozygosity is near 1 between
DDR1 and HLA-DQA1 (Fig. 2). This is, therefore, the region that more
probably carries the additional risk gene in T1D patients that present
the AH18.2 haplotype. Furthermore, AH18.2 and AH8.1 haplotypes do
not differ in their HLA-DRB and HLA-DQ genes composition and when
we remove these genes the resulting conserved region comprises only
1.65 Mb, between DDR1 and HLA-DRA loci.
In a recent paper, Nejentsev et al. published compelling evidence
that the HLA-B locus itself may confer risk of T1D independent of the
HLA-DR or DQ loci. The HLA-B18 present on the 18.2 haplotype was
speciﬁcally implicated in this study, with a strength of association just
below the one shown for the HLA-B39 allele [19]. Indeed, only the B39
and B18 alleles reached statistical signiﬁcance after conditioning on
the class II loci. Thus, it is likely that the HLA-B18 allele explains a
substantial proportion of the speciﬁc contribution of the 18.2
haplotype to T1D susceptibility, which is in agreement with our
data. However, we note that additional signals remained after
conditioning on the HLA-B locus, and it is possible that additional
alleles on the extended 18.2 haplotype may also contribute to disease
risk. On the other hand, our data suggest that the HLA-A allele carried
by the 18.2 haplotype is unlikely to contribute to T1D disease risk,
since it lies outside the highly conserved regionwe have deﬁned here.
This implies that the HLA-A contributions to disease described by
Nejentsev et al. are likely to correspond to other haplotypes. Indeed,
the A30 allele found on the AH18.2 haplotype showed no association
with T1D, after conditioning on DR, DQ and HLA-B [19].
In summary, the MHC is recognized as the most important
susceptibility region in autoimmune diseases, and provides the largest
genetic contribution toT1D risk. The AH18.2 has been often referred to
as “diabetogenic haplotype” because it confers signiﬁcantly increased
risk to T1D compared to other haplotypes that carry the same HLA-
DRB1 and DQ alleles. This high susceptibility must be due to a gene or
genes different from the HLA class II loci and one of these genes
appears to be the HLA-B18 allele, as recently described. However, we
wish to raise the possibility that there may be additional susceptibility
alleles on this haplotype, and candidates can be identiﬁed by
comparisons with other conserved haplotypes, such as AH8.1. Our
study allows us to exclude the regions telomeric to DDR1 and
centromeric to HLA-DRA as harboring the additional susceptibility
factor.
Materials and methods
Patients and controls
Ten homozygous subjects for DR3 and TNF a1b5 microsatellites: 8
T1D patients (5 female and 3male) diagnosed according to the criteria
of the American Diabetes Association (ADA) and two male controls
were recruited from the Hospital Clínico San Carlos, Madrid (Spain).
The age at onset for the T1D patients ranges from 1 to 32 years old and
all of them were insulin-dependent at the time of the study.
Twenty healthy Caucasian controls (11 female and 9 male)
homozygous for DR3 and TNF a2b3 were included in this study.
They were collected from the New York Cancer Project (NYCP) and
were cancer-free at the time of enrollment.
Genotyping
All samples were genotyped for HLA-DRB1 alleles [20,21] and for 2
microsatellite markers (TNFa and TNFb) [22] as previously described.Microsatellite alleles were ascertained using an ABI Prism 3100
automatic sequencer (Applied Biosystems, Foster City, CA, USA).
The genome-wide scan was carried out using the Illumina's
HumanHap550 Bead chip.
Statistical analysis
The call rate clean up was performed with Genetics Analysis
Software HelixTree® (© 2007 Golden Helix Inc.) version 5.3.1 (http://
www.goldenhelix.com).
The two haplotypes of each individual are reconstructed from the
genotype data using the fastPHASE program (http://stephenslab.
uchicago.edu/software.html).
To produce the plots we have used R statistical package (http://
www.r-project.org/).
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